ArticleEXCLI journal2019
The effects of L-carnitine supplementation on glycemic control: a systematic review and meta-analysis of randomized controlled trials.
Article in EXCLI journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07768228 (The Effect of L-Carnitine on Wound Healing in Patients With Diabetic Foot Ulcer.), which is not on this map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of L-Carnitine on Wound Healing in Patients With Diabetic Foot Ulcer.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The effects of L-carnitine supplementation on glycemic markers in adults: A systematic review and dose-response meta-analysis.Frontiers in nutrition · 2022Pooled it
- Acetyllevocarnitine Hydrochloride for the Treatment of Diabetic Peripheral Neuropathy: A Phase 3 Randomized Clinical Trial in China.Diabetes · 2024Trial
- Ameliorating effects of L-carnitine and synbiotic co-supplementation on anthropometric measures and cardiometabolic traits in women with obesity: a randomized controlled clinical trial.Frontiers in endocrinology · 2023Trial
- Metabolic Trajectories During Surgical Stress in Patients Undergoing Cardiac Surgery.bioRxiv : the preprint server for biology · 2025Article
- Carnitine supplementation improves insulin sensitivity and skeletal muscle acetylcarnitine formation in patients with type 2 diabetes.Diabetes, obesity & metabolism · 2025Article
- Revisiting the Role of Carnitine in Heart Disease Through the Lens of the Gut Microbiota.Nutrients · 2024Review
- Fermented Rice Bran Mitigated the Syndromes of Type 2 Diabetes in KK-Metabolites · 2024Article
- The effects of L-carnitine supplementation on cardiovascular risk factors in participants with impaired glucose tolerance and diabetes: a systematic review and dose-response meta-analysis.Diabetology & metabolic syndrome · 2024Review
- The efficacy of L-carnitine in patients with nonalcoholic steatohepatitis and concomitant obesity.Lipids in health and disease · 2023Article
- The Role of l-Carnitine in Mitochondria, Prevention of Metabolic Inflexibility and Disease Initiation.International journal of molecular sciences · 2022Review
- Re-Evaluating the Oxidative Phenotype: Can Endurance Exercise Save the Western World?Antioxidants (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The findings of trials investigating the effect of L-carnitine administration on glycemic control are controversial. This meta-analysis of randomized controlled trials (RCTs) was performed to explore the effects of L-carnitine intake on glycemic control. Two authors independently searched electronic databases including MEDLINE, EMBASE, Cochrane Library, Web of Science, PubMed and Google scholar from 1990 until February 2019, in order to find relevant RCTs. 37 studies with 44 effect sizes met the inclusion criteria and were eligible for the meta-analysis. L-carnitine supplementation resulted in a significant reduction in fasting plasma glucose (FPG) (WMD: -4.57; 95 % CI: -6.88, -2.25), insulin (WMD: -1.21; 95 % CI: -1.85, -0.57), homeostatic model assessment for insulin resistance (HOMA-IR) (WMD: -0.67; 95 % CI: -0.90, -0.44) and HbA1C concentrations (WMD: -0.30; 95 % CI: -0.47, -0.13). L-Carnitine supplementation significantly reduced FPG, insulin, HOMA-IR, and HbA1c levels.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.